Trial Profile
Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin
- Indications Advanced breast cancer; Brain metastases; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms TONIC
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 21 Mar 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2025.
- 21 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.